@FierceMedDev: UPDATED with comments from Cynvenio CEO: Cynvenio Biosystems ropes in $25M for liquid biopsy technology. FierceDiagnostics article | Follow @FierceMedDev
@VarunSaxena2: Biotie nets $56M+ in IPO, fellow Parkinson's player Cynapsus up next, followed by Intec Pharma. More from FierceDrugDelivery | Follow @VarunSaxena2
@EmilyWFierce: ICYMI yesterday: Chinese med tech gets the WHO's OK for circumcision device. Article | Follow @EmilyWFierce
> Shareholders of Wright Medical ($WMGI) and Tornier N.V. ($TRNX) approved the merger of the two companies. The deal remains subject to clearance by the U.S. Federal Trade Commission; to appease the regulator Tornier is currently pursuing divestiture of some U.S. lower extremity product lines. The deal is expected to close during the third quarter. More
> Breast reconstruction expander company AirXpanders raised AU$36.5 million (US$28.3 million) in an oversubscribed IPO on the Australian Stock Exchange and will start trading on June 22. It is planning for FDA clearance for its AeroForm at the end of 2015, with a U.S. launch in early 2016. More
> Small-cap Organovo Holdings ($ONVO), which makes bio-printed 3-D human tissues, has raised $40 million. More
Biotech News
@FierceBiotech: ICYMI yesterday: Merck KGaA hustling a promising anti-malaria drug into human studies. Report | Follow @FierceBiotech
@JohnCFierce: $TKMR down 15% on the ebola miss. | Follow @JohnCFierce
@DamianFierce: FierceBiotech Radio releases its first double album. This is our All Eyez on Me. More | Follow @DamianFierce
> Lilly and Teva tout new migraine data amid a crowded race. Story
> Antibiotics biotech Nabriva shoots for a $92M IPO. News
> Tekmira's Ebola drug comes up short in Phase II. Article
Pharma News
@FiercePharma: UPDATED: U.S. court nixes Teva's Copaxone patent--again. Report | Follow @FiercePharma
@CarlyHFierce: ICYMI: Merck inks $5.9M settlement to wrap up AzaSite off-label investigation. Article | Follow @CarlyHFierce
> Amgen's Vectibix hits PhIII survival goal in previously treated mCRC patients. Item
> Teva turns up the heat on Mylan, taking its stake past critical threshold. Story
> Celgene hits speedbump for Otezla in U.K. with NICE rejection. Article